DE69330910D1 - Arzneiabgabesystem mit stossweiser freisetzung von partikeln - Google Patents

Arzneiabgabesystem mit stossweiser freisetzung von partikeln

Info

Publication number
DE69330910D1
DE69330910D1 DE69330910T DE69330910T DE69330910D1 DE 69330910 D1 DE69330910 D1 DE 69330910D1 DE 69330910 T DE69330910 T DE 69330910T DE 69330910 T DE69330910 T DE 69330910T DE 69330910 D1 DE69330910 D1 DE 69330910D1
Authority
DE
Germany
Prior art keywords
water
coating
pellets
pct
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69330910T
Other languages
English (en)
Other versions
DE69330910T2 (de
Inventor
Chih-Ming Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Pharmaceuticals LLC
Original Assignee
Andrx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals LLC filed Critical Andrx Pharmaceuticals LLC
Publication of DE69330910D1 publication Critical patent/DE69330910D1/de
Application granted granted Critical
Publication of DE69330910T2 publication Critical patent/DE69330910T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
DE69330910T 1992-11-27 1993-11-02 Arzneiabgabesystem mit stossweiser freisetzung von partikeln Expired - Lifetime DE69330910T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/982,761 US5260069A (en) 1992-11-27 1992-11-27 Pulsatile particles drug delivery system
PCT/US1993/010643 WO1994012160A1 (en) 1992-11-27 1993-11-02 Pulsatile particles drug delivery system

Publications (2)

Publication Number Publication Date
DE69330910D1 true DE69330910D1 (de) 2001-11-15
DE69330910T2 DE69330910T2 (de) 2002-04-04

Family

ID=25529482

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330910T Expired - Lifetime DE69330910T2 (de) 1992-11-27 1993-11-02 Arzneiabgabesystem mit stossweiser freisetzung von partikeln

Country Status (10)

Country Link
US (2) US5260069A (de)
EP (1) EP0670718B1 (de)
JP (1) JPH08506802A (de)
AT (1) ATE206613T1 (de)
AU (1) AU680642B2 (de)
CA (1) CA2149152C (de)
DE (1) DE69330910T2 (de)
ES (1) ES2165869T3 (de)
NZ (1) NZ258012A (de)
WO (1) WO1994012160A1 (de)

Families Citing this family (266)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679399A (en) 1987-07-17 1997-10-21 Bio Barrier, Inc. Method of forming a membrane, especially a latex or polymer membrane, including multiple discrete layers
US5549924A (en) 1987-07-17 1996-08-27 Robin Renee Thill Shlenker Method of forming a membrane, especially a latex or polymer membrane, including a deactivating barrier and indicating layer
US5314696A (en) * 1991-06-27 1994-05-24 Paulos Manley A Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
EP0804174A4 (de) * 1993-07-21 1998-09-09 Univ Kentucky Res Found Mehrkammerhartkapseln mit kontrollierten abgabeeigenschaften
US5397574A (en) * 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
FR2723536A1 (fr) * 1994-08-11 1996-02-16 Seth Pawan Composition permettant une liberation selective d'un principe actif
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US20060067999A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
CA2275604A1 (en) * 1997-01-03 1998-07-09 Kenneth Iain Cumming Sustained release cisapride mini-tablet formulation
AU727753B2 (en) * 1997-01-14 2000-12-21 Lts Lohmann Therapie-Systeme Gmbh Expandable gastro-retentive therapeutic system with controlled active substance release in the gastro-intestinal tract
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
MY125849A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
WO1999018938A1 (en) * 1997-10-09 1999-04-22 Perio Products Ltd. Delayed total release gastrointestinal drug delivery system
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
DE69930648T2 (de) * 1998-08-12 2006-12-21 Altana Pharma Ag Orale darreichungsform für pyridin-2-ylmethylsulfinyl-1h-benzimidazole
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
WO2000025752A1 (en) * 1998-11-02 2000-05-11 Church, Marla, J. Multiparticulate modified release composition
US20090297597A1 (en) * 1998-11-02 2009-12-03 Gary Liversidge Modified Release Ticlopidine Compositions
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
JP5558648B2 (ja) 1998-11-23 2014-07-23 デイビス、ボニー アセチルコリンエステラーゼ阻害剤のための投与製剤
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
AU4221300A (en) * 1999-04-06 2000-10-23 Kamal K. Midha Pharmaceutical dosage form for pulsatile delivery of (d-threo)-methylphenidate and a second cns stimulant
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
CN102716101A (zh) 1999-10-29 2012-10-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ES2279233T3 (es) * 1999-11-17 2007-08-16 Reckitt Benckiser (Uk) Limited Recipiente soluble en agua moldeado por inyeccion.
AU1556000A (en) * 1999-11-22 2001-06-04 Akzo Nobel N.V. Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
US6669954B2 (en) 2000-01-25 2003-12-30 John R. Crison Controlled release of drugs
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6663891B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
US6667042B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6632453B2 (en) 2000-02-24 2003-10-14 Advancis Pharmaceutical Corp. Ciprofoxacin-metronidazole antibiotic composition
CA2400784C (en) * 2000-02-24 2009-05-19 Advanced Pharma, Inc. Therapeutic product, use and formulation thereof
US6627222B2 (en) 2000-02-24 2003-09-30 Advancis Pharmaceutical Corp. Amoxicillin-dicloxacillin antibiotic composition
US6623758B2 (en) * 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Cephalosporin-metronidazole antibiotic composition
US6667057B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
AU3986901A (en) * 2000-02-24 2001-09-03 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
JP2003523372A (ja) * 2000-02-24 2003-08-05 アドバンシス ファーマシューティカル コーポレイション 抗生物質及び抗真菌剤組成物
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6669948B2 (en) 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6610328B2 (en) 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
PT1276470E (pt) 2000-04-20 2007-08-13 Novartis Ag Composição de revestimento para dissimular o sabor
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US7105174B2 (en) * 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US7108859B2 (en) * 2000-10-13 2006-09-19 Advancis Pharmaceutical Corporation Antineoplastic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
EP2283829A1 (de) 2000-10-30 2011-02-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
EP1738751B1 (de) 2001-01-12 2011-05-11 Sun Pharma Advanced Research Company Ltd System zur beabstandeten Abgabe von Arzneimitteln
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
HUP0501071A3 (en) * 2001-03-13 2007-06-28 Penwest Pharmaceutical Co Chronotherapeutic dosage forms
RU2324475C2 (ru) * 2001-04-10 2008-05-20 Сан Фармасьютикал Индастриз Лимитед Состав, выделяемый в импульсном режиме в заданное время
US6663896B1 (en) 2001-08-01 2003-12-16 Alvin S. Blum Delayed release aspirin for vascular obstruction prophylaxis
US6500454B1 (en) 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US20050025824A1 (en) * 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
JP4417110B2 (ja) * 2001-12-19 2010-02-17 株式会社三和化学研究所 放出制御型成型品
JP2005523309A (ja) * 2001-12-20 2005-08-04 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法と製剤
GB0130518D0 (en) * 2001-12-21 2002-02-06 Univ Gent Pulsed bio-agent delivery systems based on degradable polymer solutions or hydrogels
AU2002236132A1 (en) * 2002-03-05 2003-09-16 Ranbaxy Laboratories Limited Modified release oral pharmaceutical composition
EP1487414A4 (de) * 2002-03-07 2007-12-12 Advancis Pharmaceutical Corp Antibiotische zusammensetzung
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US6958161B2 (en) 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
ES2295642T3 (es) * 2002-06-26 2008-04-16 Intarcia Therapeutics, Inc. Piston de volumen eficaz de ocupacion minima para sistemas de administracion de medicamentos.
EP1519717B1 (de) * 2002-07-05 2010-09-29 Temrel Limited Zusammensetzung zur kontrollierten wirkstoffabgabe
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
EP1558211A2 (de) * 2002-10-30 2005-08-03 Pharmacia Corporation Orale tabletten mit verlängerter freisetzung und verfahren für deren herstellung sowie verwendung derselben
EP1576138B1 (de) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nukleoside in kombination mit interferon und flaviviridae-mutation
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7153526B2 (en) * 2003-02-26 2006-12-26 Frank Steven R Treatment of gastrointestinal infections
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
WO2004087175A1 (en) * 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
EP2112920B1 (de) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Protonenpumpeninhibitoren enthaltende kapseln, die verschieden aufgebaute untereinheiten zur verzögerten wirkstofffreisetzung enthalten
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009364A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528189A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
EP1653925A1 (de) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robustes pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
US8246996B2 (en) 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
MXPA06003101A (es) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
MXPA06003100A (es) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis de liberacion retardada.
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
MY139427A (en) * 2004-03-26 2009-09-30 Eisai R&D Man Co Ltd Controlled-release pharmaceutical composition and method for producing the same
US7404970B2 (en) * 2004-04-13 2008-07-29 Konec, Inc. Pain relief composition, method to form same, and method to use same
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
WO2006004774A2 (en) * 2004-06-28 2006-01-12 Stanford University Laulimalide analogues as therapeutic agents
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
AU2006235483B2 (en) * 2005-04-12 2010-11-25 Elan Pharma International Limited Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1933852B1 (de) * 2005-09-27 2018-12-19 TissueTech, Inc. Amnion-zubereitungen und gereinigte zusammensetzungen und anwendungsverfahren
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
JPWO2007037259A1 (ja) * 2005-09-29 2009-04-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 生体内での崩壊性を向上させたパルス製剤
KR20080075113A (ko) * 2005-10-14 2008-08-14 하. 룬트벡 아크티에 셀스카브 에스시탈로프람 및 부프로피온을 함유하는 안정한 약학적제형
US7569605B2 (en) * 2005-10-14 2009-08-04 Forest Laboratories Holdings Limited Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
JP5334588B2 (ja) * 2005-11-28 2013-11-06 マリナス ファーマシューティカルズ ガナキソロン製剤、およびその作製方法、およびその使用
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
EA200801449A1 (ru) * 2005-12-23 2008-12-30 Лек Фармасьютиклз Д.Д. Разрывные гранулы
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
ATE510538T1 (de) 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
KR20090091321A (ko) 2006-11-28 2009-08-27 마리누스 파마슈티컬스 나노입자 제형, 이의 제조방법 및 이의 용도
CA2672602C (en) * 2006-12-18 2014-05-20 Electronic Dietary Foods Inc. Device for delivery of a substance
JP2010514777A (ja) 2006-12-26 2010-05-06 ファーマサイクリックス，インク． 併用療法においてヒストンデアセチラーゼ阻害剤を使用し、バイオマーカーをモニタする方法
US20080187579A1 (en) * 2007-02-01 2008-08-07 Pavan Bhat Extended-release dosage form
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
EP2200607A4 (de) 2007-09-10 2012-02-22 Calcimedica Inc Verbindungen als modulatoren von intrazellulärem calcium
CN104069088A (zh) * 2007-10-12 2014-10-01 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
FR2930147B1 (fr) * 2008-04-18 2013-02-08 Flamel Tech Sa Forme orale solide dotee d'un double profil de liberation
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
BRPI0917719A2 (pt) 2008-08-27 2019-11-19 Calcimedica Inc compostos que modulam cálcio intracelular
CN102238946B (zh) * 2008-11-07 2014-11-26 株式会社三养生物制药 用于哌醋甲酯的控制释放的药物组合物
WO2010071866A2 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
US20110311628A1 (en) 2009-03-09 2011-12-22 Council Of Scientific And Industrial Research Pulsatile release composition of therapeutic agent
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
WO2010124296A2 (en) 2009-04-24 2010-10-28 Tissuetech, Inc. Compositions containing hc•ha complex and methods of use thereof
US8808257B2 (en) 2009-08-31 2014-08-19 Johnson & Johnson Vision Care, Inc. Methods and apparatus for pulsatile release of medicaments from a punctal plug
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CA2782285A1 (en) 2009-12-02 2011-06-09 Luigi Mapelli Fexofenadine microcapsules and compositions containing them
EP2558866B1 (de) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potenzierung einer antikrebs-wirkung durch eine kombinationstherapie mit ber-pfad-hemmern
US8754219B2 (en) 2010-04-27 2014-06-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2563776B1 (de) 2010-04-27 2016-06-08 Calcimedica, Inc. Verbindungen als modulatoren von intrazellulärem calcium
ES2688072T3 (es) 2010-05-11 2018-10-30 Mallinckrodt Ard Ip Limited ACTH para el tratamiento de la esclerosis lateral amiotrófica
MX337711B (es) 2010-08-27 2016-03-15 Calcimedica Inc Compuestos que modulan el calcio intracelular.
US8796416B1 (en) 2010-10-25 2014-08-05 Questcor Pharmaceuticals, Inc ACTH prophylactic treatment of renal disorders
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
US9763884B2 (en) 2011-05-13 2017-09-19 Eb Ip Hybritabs B.V. Drug delivery system
CA2837878A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US9492423B2 (en) 2011-09-13 2016-11-15 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
EP2586429A1 (de) 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Arzneimittelabgabevorrichtung mit mehreren Einheiten für pulsierende oder verzögerte Freisetzung
US20140326056A1 (en) * 2011-11-30 2014-11-06 D.E.S. Diagnostics Ltd Method for Quick Assessment of Osmolarity
US20140357971A1 (en) * 2011-11-30 2014-12-04 Diagnostear Ltd. Dry eye diagnostic
WO2013082476A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
LT3326611T (lt) 2012-02-22 2020-08-25 Duchesnay Inc. Doksilamino ir piridoksino ir (arba) jų metabolitų ar druskų vaisto forma
JP2015528001A (ja) 2012-07-11 2015-09-24 ティッシュテック，インク． Ｈｃ−ｈａ／ｐｔｘ３複合体を含む組成物およびその使用方法
CA2885828C (en) 2012-09-28 2021-04-27 University Of Washington Through Its Center For Commercialization Ureido-thiophenyl derivatives, compositions thereof and methods for preventing, treating and/or protecting against sensory hair cell death
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
PL2732803T3 (pl) * 2012-11-19 2018-10-31 Follmann Gmbh & Co. Kg Termicznie otwierające się stabilne mikrokapsułki z rdzeniem/powłoką
EP2941244A4 (de) * 2013-01-02 2016-09-07 Eatlittle Inc Pseudobezoar-basiertes intraluminales magen/darm-transplantat
GB201303781D0 (en) 2013-03-04 2013-04-17 Gauthier Pierre Pascal Oral timer device and method of using same
WO2014153221A2 (en) 2013-03-14 2014-09-25 Questcor Pharmaceuticals, Inc. Acth for treatment of acute respiratory distress syndrome
JP6379194B2 (ja) 2013-07-22 2018-08-22 デュシネイ・インコーポレイテッド 悪心及び嘔吐の管理のための組成物
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2930228A1 (en) 2013-11-11 2015-05-14 Limoxifen B.V. Methods and pharmaceutical formulations for treatment of selective estrogen-receptor modulator-induced adverse drug reactions
WO2015073736A1 (en) 2013-11-13 2015-05-21 Arbor Pharmaceuticals, Llc Methods and compositions for treating adhd
BR112016012728A2 (pt) 2013-12-05 2020-08-11 Pharmacyclics Llc compostos inibidores de tirosina quinase de bruton, composição farmacêutica os compreendendo e uso dos mesmos
CN106163564B (zh) * 2014-04-08 2018-10-09 陶氏环球技术有限责任公司 包含酯化纤维素醚的分散体
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10174275B2 (en) 2015-01-30 2019-01-08 Follmann Gmbh & Co. Kg Thermally opening stable core/shell microcapsules
US10399994B2 (en) 2015-02-06 2019-09-03 University Of Washington Compounds and methods for preventing or treating sensory hair cell death
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
WO2016138025A2 (en) 2015-02-23 2016-09-01 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
EA039121B1 (ru) 2015-02-27 2021-12-07 Куртана Фармасьютикалс, Инк. ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
WO2016178083A2 (en) 2015-05-01 2016-11-10 Diagnostear, Ltd. Method for measuring tear constitutents in a tear sample
CN107847526A (zh) 2015-05-20 2018-03-27 组织技术公司 用于预防上皮细胞的增殖和上皮‑间充质转换的组合物和方法
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
WO2017004526A1 (en) 2015-07-02 2017-01-05 University Of Louisville Research Foundation, Inc. EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER
ES2952064T3 (es) 2015-12-16 2023-10-26 Walter & Eliza Hall Inst Medical Res Inhibición de la proteína SH2 inducida por citocinas en células NK
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
WO2017205534A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
GB2551980A (en) * 2016-06-30 2018-01-10 Commw Scient Ind Res Org Method and system for low level metal analysis of mineral samples
EP3481387A4 (de) 2016-08-11 2020-04-08 Ovid Therapeutics Inc Verfahren und zusammensetzungen zur behandlung von epileptischen erkrankungen
KR102468670B1 (ko) 2016-08-26 2022-11-17 커타나 파마슈티칼스, 인크. Olig2 활성의 억제
EP3565580B1 (de) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Kontinuierlicher verabreichung von exenatid und co-verabreichung von acetaminophen, ethinylestradiol oder levonorgestrel
WO2019039937A1 (en) 2017-08-21 2019-02-28 Stichting Vumc POLYTHERAPY FOR THE TREATMENT OF CANCER
EP3706735A1 (de) 2017-11-06 2020-09-16 Snap Bio, Inc. Pim-kinaseinhibitorzusammensetzungen, verfahren und ihre verwendungen
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
TW202019887A (zh) 2018-07-27 2020-06-01 美商同心止痛劑股份有限公司 酚系trpv1促效劑之聚乙二醇化前藥
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
BR112021011578A2 (pt) 2018-12-31 2021-08-31 Biomea Fusion, Llc Inibidores irreversíveis de interação menina-mll
EP3937938A1 (de) 2019-03-15 2022-01-19 Unicycive Therapeutics Inc. Nicorandilderivate
JP2022543837A (ja) 2019-08-05 2022-10-14 マリナス ファーマシューティカルズ， インコーポレイテッド てんかん重積状態の治療に使用するためのガナキソロン
CA3158280A1 (en) 2019-12-06 2021-06-10 Alex Aimetti Ganaxolone for use in treating tuberous sclerosis complex
CA3202151A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
CA3204457A1 (en) 2021-01-06 2022-07-14 Ben SESSA Mdma in the treatment of alcohol use disorder
WO2022238507A1 (en) 2021-05-11 2022-11-17 Awakn Ls Europe Holdings Limited Therapeutic aminoindane compounds and compositions
CA3221280A1 (en) 2021-06-03 2022-12-08 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
WO2023139163A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-benzodioxole esters and their therapeutic use
WO2023156565A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL52914C (de) * 1937-11-24
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
JPH0759499B2 (ja) * 1984-02-10 1995-06-28 ベンツォン ファーマ エイ／エス 拡散被覆された複合単位服用剤
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
ATE90203T1 (de) * 1989-03-17 1993-06-15 Pitman Moore Inc Kontrollierte, verzoegerte wirkstofffreisetzung von makromolekularen proteinen.
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5017381A (en) * 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system

Also Published As

Publication number Publication date
CA2149152C (en) 2003-09-30
WO1994012160A1 (en) 1994-06-09
AU680642B2 (en) 1997-08-07
NZ258012A (en) 1996-10-28
EP0670718A4 (de) 1996-10-09
CA2149152A1 (en) 1994-06-09
ATE206613T1 (de) 2001-10-15
US5260069A (en) 1993-11-09
AU5549294A (en) 1994-06-22
JPH08506802A (ja) 1996-07-23
US5472708A (en) 1995-12-05
ES2165869T3 (es) 2002-04-01
EP0670718A1 (de) 1995-09-13
EP0670718B1 (de) 2001-10-10
DE69330910T2 (de) 2002-04-04

Similar Documents

Publication Publication Date Title
DE69330910D1 (de) Arzneiabgabesystem mit stossweiser freisetzung von partikeln
ATE215818T1 (de) Multipartikel-arzneistoffabgabesystem mit stossweiser freisetzung
KR890006223A (ko) 약물방출계
KR920703026A (ko) 부하제를 포함한 장기간 전달 장치
NZ508567A (en) Methods and devices for providing prolonged drug therapy
ATE165734T1 (de) Arzneitablette, die befähigt ist, einen oder mehrere wirkstoffe mit unterschiedlichen abgaberaten freizusetzen
ATE269709T1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
ZA912380B (en) Osmotic dosage system for liquid drug delivery
EP1014952A1 (de) Aus einer vielzahl von kleineinheiten aufgebaute brausedosisform
ATE285228T1 (de) Arzneistoffverabreichungsystem zur verzögerten, völlstandigen wirkstoffabgabe im verdauungstrakt
DK0673645T3 (da) Farmaceutisk præparat til afgivelse af lægemidler i colon
JPS62267221A (ja) 新規薬物製剤
ATE211649T1 (de) Dosisform mit gesteuerter freigabe für kalium
IE882898L (en) Solubility modulated drug delivery device
Helfand et al. Evolution of pharmaceutical oral dosage forms
KR940701285A (ko) 소수성 부하물을 함유하는 지효성 전달 장치
US4454142A (en) Hyperkinetic child treatment agent
Freed et al. Amphetamine-resin complex for prolonged appetite suppression
US6663896B1 (en) Delayed release aspirin for vascular obstruction prophylaxis
CN100522168C (zh) 罗通定缓释胶囊及其制备方法
TH34365A (th) รูปขนาดใช้ยาที่เกิดเป็นฟองซึ่งเป็นหน่วยรวม

Legal Events

Date Code Title Description
8364 No opposition during term of opposition